Evaluation of drug loading, pharmacokinetic behavior, and toxicity of a cisplatin-containing hydrogel nanoparticle

Journal of Controlled Release

Volumn 204, Issue , 2015, Pages 70-77

  Kai, Marc P ^a   Keeler, Amanda W ^b   Perry, Jillian L ^b   Reuter, Kevin G ^c   Luft, J Christopher ^b   O'Neal, Sara K ^b   Zamboni, William C ^b   Desimone, Joseph M ^a,b,c  

^a North Carolina State University   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c University of North Carolina at Chapel Hill   (United States)

Author keywords

Cisplatin; Cytotoxicity; PEGylation; Pharmacokinetics; PRINT

Indexed keywords

BIOLOGICAL ORGANS; CELL CULTURE; CYTOTOXICITY; DISEASES; DRUG THERAPY; HYDROGELS; NANOPARTICLES; PHARMACOKINETICS; PLATINUM COMPOUNDS; PRINTING; TUMORS; WETTING;

AREA UNDER THE CURVES; CIS-PLATIN; ENHANCED PERMEATION AND RETENTIONS; HYDROGEL NANOPARTICLES; NANOPARTICLE FORMULATION; PEGYLATION; PHARMACOKINETIC PROFILES; POLYMERIC HYDROGELS;

TOXICITY;

CISPLATIN; NANOPARTICLE; ANTINEOPLASTIC AGENT; DRUG CARRIER; HYDROGEL;

AREA UNDER THE CURVE; ARTICLE; CANCER CELL LINE; COMPLEX FORMATION; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG DOSE COMPARISON; DRUG SCREENING; HUMAN; HUMAN CELL; HYDROGEL; PRIORITY JOURNAL; RENAL PROTECTION; SURFACE PROPERTY; SUSTAINED DRUG RELEASE; VOLUME OF DISTRIBUTION; ANIMAL; C57BL MOUSE; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; DRUG FORMULATION; MAXIMUM TOLERATED DOSE; NEOPLASMS, EXPERIMENTAL; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DRUG CARRIERS; DRUG COMPOUNDING; HYDROGELS; MAXIMUM TOLERATED DOSE; MICE, INBRED C57BL; NANOPARTICLES; NEOPLASMS, EXPERIMENTAL;

EID: 84924368369     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2015.03.001     Document Type: Article

References (61)

1. D.-W. Shen, L.M. Pouliot, M.D. Hall, and M.M. Gottesman Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes Pharmacol. Rev. 64 2012 706 721 10.1124/pr.111.005637
2. X. Yao, K. Panichpisal, N. Kurtzman, and K. Nugent Cisplatin nephrotoxicity: a review Am. J. Med. Sci. 334 2007 115 124 10.1097/MAJ.0b013e31812dfe1e
3. M.E. Davis, Z.G. Chen, and D.M. Shin Nanoparticle therapeutics: an emerging treatment modality for cancer Nat. Rev. Drug Discov. 7 2008 771 782 10.1038/nrd2614
4. Y. Matsumura, and H. Maeda A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs Cancer Res. 46 1986 6387 6392 (http://www.ncbi.nlm.nih.gov/pubmed/2946403)
5. J.L. Arias, L.H. Reddy, and P. Couvreur Polymeric nanoparticulate system augmented the anticancer therapeutic efficacy of gemcitabine J. Drug Target. 17 2009 586 598 10.1080/10611860903105739
6. H. Hatakeyama, H. Akita, and H. Harashima A multifunctional envelope type nano device (MEND) for gene delivery to tumours based on the EPR effect: a strategy for overcoming the PEG dilemma Adv. Drug Deliv. Rev. 63 2011 152 160 10.1016/j.addr.2010.09.001
7. S.-D. Li, and L. Huang Surface-modified LPD nanoparticles for tumor targeting Ann. N. Y. Acad. Sci. 1082 2006 1 8 10.1196/annals.1348.001
8. H. Maeda, J. Wu, T. Sawa, Y. Matsumura, and K. Hori Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review J. Control. Release 65 2000 271 284 (http://www.ncbi.nlm.nih.gov/pubmed/10699287)
9. Y.-C. Tseng, S. Mozumdar, and L. Huang Lipid-based systemic delivery of siRNA Adv. Drug Deliv. Rev. 61 2009 721 731 10.1016/j.addr.2009.03.003
10. A.L. van de Ven, P. Kim, O. Haley, J.R. Fakhoury, G. Adriani, and J. Schmulen et al. Rapid tumoritropic accumulation of systemically injected plateloid particles and their biodistribution J. Control. Release 158 2012 148 155 10.1016/j.jconrel.2011.10.021
11. D.C. Drummond, O. Meyer, K. Hong, D.B. Kirpotin, and D. Papahadjopoulos Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors Pharmacol. Rev. 51 1999 691 743 (http://www.ncbi.nlm.nih.gov/pubmed/10581328, accessed July 23, 2013)
12. R. Gref, M. Lück, P. Quellec, M. Marchand, E. Dellacherie, and S. Harnisch et al. "Stealth" corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption Colloids Surf. B: Biointerfaces 18 2000 301 313 (http://www.ncbi.nlm.nih.gov/pubmed/10915952, accessed March 31, 2011)
13. S.M. Moghimi, I.S. Muir, L. Illum, S.S. Davis, and V. Kolb-Bachofen Coating particles with a block co-polymer (poloxamine-908) suppresses opsonization but permits the activity of dysopsonins in the serum Biochim. Biophys. Acta 1179 1993 157 165 (http://www.ncbi.nlm.nih.gov/pubmed/8218358)
14. D.E. Owens, and N.A. Peppas Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles Int. J. Pharm. 307 2006 93 102 10.1016/j.ijpharm.2005.10.010
15. D. Papahadjopoulos, T.M. Allen, A. Gabizon, E. Mayhew, K. Matthay, and S.K. Huang et al. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy Proc. Natl. Acad. Sci. U. S. A. 88 1991 11460 11464 (http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=53155&tool=pmcentrez&rendertype=abstract, accessed July 23, 2013)
16. T. Boulikas, and M. Vougiouka Cisplatin and platinum drugs at the molecular level. (Review) Oncol. Rep. 10 2003 1663 1682 (http://www.ncbi.nlm.nih.gov/pubmed/14534679)
17. M.C. Bibby Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages Eur. J. Cancer 40 2004 852 857 10.1016/j.ejca.2003.11.021
18. L. Peng, L. Feng, H. Yuan, S.R. Benhabbour, and R.J. Mumper Development of a novel orthotopic non-small cell lung cancer model and therapeutic benefit of 2′-(2-bromohexadecanoyl)-docetaxel conjugate nanoparticles Nanomedicine 2014 1 10 10.1016/j.nano.2014.03.016
19. F. Alexis, E. Pridgen, L.K. Molnar, and O.C. Farokhzad Factors affecting the clearance and biodistribution of polymeric nanoparticles Mol. Pharm. 5 2008 505 515 10.1021/mp800051m
20. S.M. Moghimi, A.C. Hunter, and T.L. Andresen Factors controlling nanoparticle pharmacokinetics: an integrated analysis and perspective Annu. Rev. Pharmacol. Toxicol. 52 2012 481 503 10.1146/annurev-pharmtox-010611-134623
21. A.E. Nel, L. Mädler, D. Velegol, T. Xia, E.M.V. Hoek, and P. Somasundaran et al. Understanding biophysicochemical interactions at the nano-bio interface Nat. Mater. 8 2009 543 557 10.1038/nmat2442
22. A. Vonarbourg, C. Passirani, P. Saulnier, and J.-P. Benoit Parameters influencing the stealthiness of colloidal drug delivery systems Biomaterials 27 2006 4356 4373 10.1016/j.biomaterials.2006.03.039
23. M.R. Dreher, W. Liu, C.R. Michelich, M.W. Dewhirst, F. Yuan, and A. Chilkoti Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers J. Natl. Cancer Inst. 98 2006 335 344 10.1093/jnci/djj070
24. R.K. Jain, and T. Stylianopoulos Delivering nanomedicine to solid tumors Nat. Rev. Clin. Oncol. 7 2010 653 664 10.1038/nrclinonc.2010.139
25. S.D. Perrault, C. Walkey, T. Jennings, H.C. Fischer, and W.C.W. Chan Mediating tumor targeting efficiency of nanoparticles through design Nano Lett. 9 2009 1909 1915 10.1021/nl900031y
26. F. Braet, E. Wisse, P. Bomans, P. Frederik, W. Geerts, and A. Koster et al. Contribution of high-resolution correlative imaging techniques in the study of the liver sieve in three-dimensions Microsc. Res. Tech. 242 2007 230 242 10.1002/jemt
27. F.R. Kersey, T.J. Merkel, J.L. Perry, M.E. Napier, and J.M. Desimone Effect of aspect ratio and deformability on nanoparticle extravasation through nanopores Langmuir 2012 10.1021/la301279v
28. R.E. Mebius, and G. Kraal Structure and function of the spleen Nat. Rev. Immunol. 5 2005 606 616 10.1038/nri1669
29. T.J. Merkel, S.W. Jones, K.P. Herlihy, F.R. Kersey, A.R. Shields, and M. Napier et al. Using mechanobiological mimicry of red blood cells to extend circulation times of hydrogel microparticles Proc. Natl. Acad. Sci. U. S. A. 108 2011 586 591 10.1073/pnas.1010013108
30. S. Venkataraman, J.L. Hedrick, Z.Y. Ong, C. Yang, P.L.R. Ee, and P.T. Hammond et al. The effects of polymeric nanostructure shape on drug delivery Adv. Drug Deliv. Rev. 63 2011 1228 1246 10.1016/j.addr.2011.06.016
31. Y. Geng, P. Dalhaimer, S. Cai, R. Tsai, M. Tewari, and T. Minko et al. Shape effects of filaments versus spherical particles in flow and drug delivery Nat. Nanotechnol. 2 2007 249 255 10.1038/nnano.2007.70
32. J. Park, G. Von Maltzahn, L. Zhang, A.M. Derfus, D. Simberg, and T.J. Harris et al. Systematic surface engineering of magnetic nanoworms for in vivo tumor targeting Blood 92121 2009 694 700 10.1002/smll.200801789
33. J.A. Champion, Y.K. Katare, and S. Mitragotri Particle shape: a new design parameter for micro- and nanoscale drug delivery carriers J. Control. Release 121 2007 3 9 10.1016/j.jconrel.2007.03.022
34. P. Decuzzi, B. Godin, T. Tanaka, S.-Y. Lee, C. Chiappini, and X. Liu et al. Size and shape effects in the biodistribution of intravascularly injected particles J. Control. Release 141 2010 320 327 10.1016/j.jconrel.2009.10.014
35. O. Garbuzenko, S. Zalipsky, M. Qazen, and Y. Barenholz Electrostatics of PEGylated micelles and liposomes containing charged and neutral lipopolymers Langmuir 21 2005 2560 2568 10.1021/la0479105
36. R.K. Jain Transport of molecules, particles, and cells in solid tumors Annu. Rev. Biomed. Eng. 1 1999 241 263 10.1146/annurev.bioeng.1.1.241
37. D.P. Lankveld, R.G. Rayavarapu, P. Krystek, A.G. Oomen, H.W. Verharen, and T.G. van Leeuwen et al. Blood clearance and tissue distribution of PEGylated and non-PEGylated gold nanorods after intravenous administration in rats Nanomedicine (London) 6 2011 339 349 10.2217/nnm.10.122
38. C.D. Walkey, J.B. Olsen, H. Guo, A. Emili, and W.C.W. Chan Nanoparticle size and surface chemistry determine serum protein adsorption and macrophage uptake J. Am. Chem. Soc. 134 2012 2139 2147 10.1021/ja2084338
39. L.E. Euliss, J.A. DuPont, S. Gratton, and J. DeSimone Imparting size, shape, and composition control of materials for nanomedicine Chem. Soc. Rev. 35 2006 1095 1104 10.1039/b600913c
40. J.P. Rolland, B.W. Maynor, L.E. Euliss, A.E. Exner, G.M. Denison, and J.M. DeSimone Direct fabrication and harvesting of monodisperse, shape-specific nanobiomaterials J. Am. Chem. Soc. 127 2005 10096 10100 10.1021/ja051977c
41. J.L. Perry, K.G. Reuter, M.P. Kai, K.P. Herlihy, S.W. Jones, J.C. Luft, M. Napier, J.E. Bear, and J.M. DeSimone PEGylated PRINT nanoparticles: the impact of PEG density on protein binding, macrophage association, biodistribution, and pharmacokinetics Nano Lett. 12 2012 5304 5310 10.1021/nl302638g
42. J. Guzmán, M.T. Iglesias, E. Riande, V. Compañ, and A. Andrio Synthesis and polymerization of acrylic monomers with hydrophilic long side groups. Oxygen transport through water swollen membranes prepared from these polymers Polymer (Guildf) 38 1997 5227 5232 10.1016/S0032-3861(97)00039-6
43. E.M. Enlow, J.C. Luft, M.E. Napier, and J.M. DeSimone Potent engineered PLGA nanoparticles by virtue of exceptionally high chemotherapeutic loadings Nano Lett. 11 2011 808 813 10.1021/nl104117p
44. Y. Zhang, M. Huo, J. Zhou, and S. Xie PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel Comput. Methods Programs Biomed. 99 2010 306 314 10.1016/j.cmpb.2010.01.007
45. H. Akaike A new look at the statistical model identification IEEE Trans. Autom. Control 19 1974 716 723 10.1109/TAC.1974.1100705
46. A.J. Combest, P.J. Roberts, P.M. Dillon, K. Sandison, S.K. Hanna, and C. Ross et al. Genetically engineered cancer models, but not xenografts, faithfully predict anticancer drug exposure in melanoma tumors Oncologist 17 2012 1303 1316 10.1634/theoncologist. 2012-0274
47. J.G. Morrison, P. White, S. McDougall, J.W. Firth, S.G. Woolfrey, and M.A. Graham et al. Validation of a highly sensitive ICP-MS method for the determination of platinum in biofluids: application to clinical pharmacokinetic studies with oxaliplatin J. Pharm. Biomed. Anal. 24 2000 1 10 (http://www.ncbi.nlm.nih.gov/pubmed/11108533)
48. M. Yokoyama, T. Okano, Y. Sakurai, S. Suwa, and K. Kataoka Introduction of cisplatin into polymeric micelle J. Control. Release 39 1996 351 356 10.1016/0168-3659(95)00165-4
49. S.E. Gratton, P.D. Pohlhaus, J. Lee, J. Guo, M.J. Cho, and J.M. Desimone Nanofabricated particles for engineered drug therapies: a preliminary biodistribution study of PRINT nanoparticles J. Control. Release 121 2007 10 18 10.1016/j.jconrel.2007.05.027
50. M.C. Parrott, M. Finniss, J.C. Luft, A. Pandya, A. Gullapalli, and M.E. Napier et al. Incorporation and controlled release of silyl ether prodrugs from PRINT nanoparticles J. Am. Chem. Soc. 134 2012 7978 7982 10.1021/ja301710z
51. J. Wang, S. Tian, R.A. Petros, M.E. Napier, and J.M. Desimone The complex role of multivalency in nanoparticles targeting the transferrin receptor for cancer therapies J. Am. Chem. Soc. 132 2010 11306 11313 10.1021/ja1043177
52. K.J. Harrington, C.R. Lewanski, A.D. Northcote, J. Whittaker, H. Wellbank, and R.G. Vile et al. Phase I-II study of pegylated liposomal cisplatin (SPI-077) in patients with inoperable head and neck cancer Ann. Oncol. 12 2001 493 496 (http://www.ncbi.nlm.nih.gov/pubmed/11398881, accessed July 23, 2013)
53. G.J. Veal, M.J. Griffin, E. Price, A. Parry, G.S. Dick, and M.A. Little et al. A phase I study in paediatric patients to evaluate the safety and pharmacokinetics of SPI-77, a liposome encapsulated formulation of cisplatin Br. J. Cancer 84 2001 1029 1035 10.1054/bjoc.2001.1723
54. T.L. Cornelison, and E. Reed Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin Gynecol. Oncol. 50 1993 147 158 10.1006/gyno.1993.1184
55. J.L. Marshall Maximum-tolerated dose, optimum biologic dose, or optimum clinical value: dosing determination of cancer therapies J. Clin. Oncol. 30 2012 2815 2816 10.1200/JCO.2012.43.4233
56. M.S. Newman, G.T. Colbern, P.K. Working, C. Engbers, and M.A. Amantea Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice Cancer Chemother. Pharmacol. 43 1999 1 7 (http://www.ncbi.nlm.nih.gov/pubmed/9923534)
57. P. Sengupta, S. Basu, S. Soni, A. Pandey, B. Roy, and M.S. Oh et al. Cholesterol-tethered platinum II-based supramolecular nanoparticle increases antitumor efficacy and reduces nephrotoxicity Proc. Natl. Acad. Sci. U. S. A. 109 2012 11294 11299 10.1073/pnas.1203129109
58. L. Cheng, C. Jin, W. Lv, Q. Ding, and X. Han Developing a highly stable PLGA-mPEG nanoparticle loaded with cisplatin for chemotherapy of ovarian cancer PLoS One 6 2011 e25433 10.1371/journal.pone.0025433
59. P. Devarajan, R. Tarabishi, J. Mishra, Q. Ma, A. Kourvetaris, and M. Vougiouka et al. Low renal toxicity of lipoplatin compared to cisplatin in animals Anticancer Res. 24 2004 2193 2200 (http://www.ncbi.nlm.nih.gov/pubmed/15330160)
60. N. Nishiyama, S. Okazaki, H. Cabral, M. Miyamoto, Y. Kato, and Y. Sugiyama et al. Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice Cancer Res. 63 2003 8977 8983 (http://www.ncbi.nlm.nih.gov/pubmed/14695216, accessed October 02, 2012)
61. S.R. MacEwan, D.J. Callahan, and A. Chilkoti Stimulus-responsive macromolecules and nanoparticles for cancer drug delivery Nanomedicine (London) 5 2010 793 806 10.2217/nnm.10.50